The danger of Z-drugs for dementia patients

Published by  Communications

On 24th Nov 2020

Strong sleeping pills known as ‘Z-drugs’ are linked with an increased risk of falls, fractures and stroke among people with dementia – according to research from the University of East Anglia.

Sleep disturbance is common among people with dementia and the impact for patients and their families is significant.

To date there are no proven effective treatments available, however people with dementia are often prescribed Z-drugs (zopiclone, zaleplon, and zolpidem).

But a new study published today reveals that stronger doses of these drugs are linked with an increased risk of adverse effects.

These adverse effects were found to be similar or greater than those for higher dose benzodiazepines or ‘benzos’ – which are also used to treat sleep disturbance, and are known to have several adverse effects.

The team say that patients already taking higher doses of Z-drugs should not stop taking their medication suddenly, however they should seek a review with their GP.

Prof Chris Fox, from UEA’s Norwich Medical School, said: “As many as 90 per cent of people with dementia suffer sleep disturbances and it has a big impact on their mental and physical health, as well as that of their carers.

“Z-drugs are commonly prescribed to help people sleep - however these medicines were never licensed for dementia and they have been associated with adverse events such as falls and fracture risks in older people.

“We wanted to find out how they affect people with dementia, who are frequently prescribed them to help with sleep disturbance.”

The team analysed data from 27,090 patients in England diagnosed with dementia between January 2000 and March 2016. The average age of the patients was 83 and 62 per cent were women.

They looked at the adverse events for 3,532 patients who had been prescribed Z-drugs and compared them to people suffering sleep disturbance who had not been prescribed sedatives, and patients who had been prescribed benzodiazepines.

They also looked to see whether Z-drug dosage played a part in adverse outcomes.

Prof Fox said: “We studied a range of adverse outcomes including fractures, falls, deep vein thrombosis, stroke and death – over two years. And we were particularly interested to see whether higher doses led to worse outcomes.”

Higher dose Z-drugs and benzodiazepines were defined as prescriptions equivalent to ≥7.5mg zopiclone or >5mg diazepam daily.

“For patients prescribed Z-drugs, 17 per cent were given higher doses. And we found that these patients on higher doses were more at risk of falls and fractures, particularly hip fractures, and stroke – compared with patients who were not taking any medication for sleep disturbance,” said Prof Fox.

Those on lower doses however (≤3.75mg zopiclone or equivalent) were not found to have an increased risk of adverse outcomes. 

And there were no differences in adverse events for Z-drugs compared to benzodiazepines, except lower mortality rates with Z-drugs.

Prof Fox said: “This research shows us that higher dose Z-drugs should be avoided, if possible, in people living with dementia, and non-pharmacological alternatives preferentially considered.

“Patients already taking higher dose Z-drugs should not stop taking their medication, but we recommend that they should make an appointment to see their GP for a review,” he added.

Prof Clive Ballard, of the University of Exeter Medical School, who collaborated on the study, said: “Our findings serve an important caution regarding the harms of sleeping tablets in people with dementia.

“This research is a very timely and unfortunately necessary reminder that sedative medications are not a helpful way to manage social isolation during Covid-19. 

“Our study also highlights the importance of research to develop non-drug approaches to help people with dementia to sleep – whether they are at home or in residential care.”

Dr Ian Maidment, Reader in Clinical Pharmacy at Aston University and lead pharmacist on the study, said: “Z-drugs are widely used to treat insomnia in people living with dementia, but are only recommended as a short-term treatment for the maximum of four weeks. Our work shows the importance of clinicians including GPs and pharmacists reviewing patients on long-term Z-drugs.”

The study was led by UEA, in collaboration with researchers from The Quadram Institute, Aston University, University College London, and the University of Exeter.

Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study’ is published in the journal BMC Medicine on November 24, 2020.

Latest News

  News
28 Jan 2021

How AI and ‘puff technology’ could help understanding of smoking behaviour

Researchers at the University of East Anglia are using new ‘puff technology’ to see how people who smoke and vape use e-cigarettes.

Read more >
  News
25 Jan 2021

Continued strict control measures needed to reduce new COVID-19 strains

A group of scientists is calling on governments to consider the continued use of strict control measures as the only way to reduce the evolution and spread of...

Read more >
  News
22 Jan 2021

"Timing wise, this U-turn in US climate policy is excellent"

As President Biden signs the United States back up to the UN Paris Agreement, Heike Schroeder, professor of environmental governance in UEA’s School of...

Read more >
  News
21 Jan 2021

Herd immunity may not be achievable even with high vaccine uptake

The government vaccination programme may not be sufficient to achieve herd immunity - even if everyone in the UK is vaccinated - according to new research from...

Read more >
Are you searching for something?
  News
21 Jan 2021

Herd immunity may not be achievable even with high vaccine uptake

The government vaccination programme may not be sufficient to achieve herd immunity - even if everyone in the UK is vaccinated - according to new research from...

Read more >
  News
20 Jan 2021

Study shows how network of marine protected areas could help safeguard Antarctic penguins

New research led by BirdLife International, the University of East Anglia (UEA) and British Antarctic Survey highlights how a proposed network of marine...

Read more >
  News
19 Jan 2021

New report on post-Brexit challenges and opportunities

Brexit and Beyond, a new report from academic think tank UK in a Changing Europe, underlines the challenges and opportunities that confront the United Kingdom...

Read more >
  News
19 Jan 2021

‘Babysitters’ provide boost to offspring of elderly birds

Young Seychelles warblers fare better if their elderly parents have help raising them, according to new research from the University of East Anglia (UEA) and the...

Read more >
  News
15 Jan 2021

New project aims to improve rates of patients taking medicines for type 2 diabetes

The University of East Anglia (UEA) is working with the Universities of Oxford and Amsterdam to test a community pharmacy service designed to support people with...

Read more >
  News
14 Jan 2021

2020 ends earth’s warmest 10 years on record

The latest data confirms 2020 concludes the earth’s warmest 10-year period on record.

Read more >
  News
11 Jan 2021

The true cost of chemotherapy

Chemotherapy for breast cancer costs the UK economy more than £248 million annually, including ‘out-of-pocket’ personal costs of more than £1,000 per patient –...

Read more >